Hikal Limited (IN:HIKAL)
:HIKAL
Want to see IN:HIKAL full AI Analyst Report?
HIKAL Stock Chart & Stats
₹227.05
-₹7.35(-1.92%)
At close: 4:00 PM EST
₹227.05
-₹7.35(-1.92%)
Day’s Range― - ―
52-Week Range₹145.95 - ₹372.40
Previous CloseN/A
Volume141.84K
Average Volume (3M)34.88K
Market Cap
₹26.70B
Enterprise Value₹30.12B
Total Cash (Recent Filing)₹456.00M
Total Debt (Recent Filing)₹6.84B
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.58%
Share Statistics
EPS (TTM)-3.96
Shares Outstanding123,300,750
10 Day Avg. Volume44,586
30 Day Avg. Volume34,881
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.51
Price to Sales (P/S)1.06
P/FCF Ratio20.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.1
Revenue Forecast (FY)₹19.62B
Bulls Say, Bears Say
Bulls Say
Business-model DiversificationHikal’s dual focus on CDMO services and manufacture of pharma and crop-protection intermediates creates diversified revenue streams. Long-term supply agreements and development-to-commercialization services foster customer stickiness and recurring manufacturing income, supporting structural resilience.
Positive Cash GenerationDespite reporting a net loss, Hikal converted operations into cash with positive free cash flow in 2026. Persistent positive cash generation improves ability to service debt, fund necessary capex for manufacturing capacity, and maintain operational continuity without immediate external financing.
Manageable LeverageDeclining debt and leverage at ~25% of assets provide financial flexibility for a manufacturing firm. Lower leverage reduces default risk and preserves capacity to invest in scale-up, technology transfer, or to absorb cyclical swings while supporting credit access for strategic investments.
Bears Say
Profitability DeteriorationA swing to net losses indicates margin compression and elevated operating costs that weaken internal capital formation. Sustained unprofitability would impair reinvestment capacity, constrain discretionary spend on R&D or capacity, and may strain customer trust for long-term contracts.
Inconsistent Revenue TrendsIrregular top-line performance complicates capacity utilization and fixed-cost absorption in a capital-intensive manufacturing business. Cyclical or lumpy CDMO revenues raise the risk of underused assets, margin volatility, and difficulty in forecasting cash flows for multi-year contract commitments.
Volatile Cash ConversionMaterial swings in free cash flow signal uneven cash conversion and make multi-year planning harder. For a manufacturer, this volatility can force timing-dependent external financing, delay capex or maintenance, and increase vulnerability during downturns despite occasional positive FCF years.
Hikal Limited News
HIKAL FAQ
What was Hikal Limited’s price range in the past 12 months?
Hikal Limited lowest stock price was ₹145.95 and its highest was ₹372.40 in the past 12 months.
What is Hikal Limited’s market cap?
Hikal Limited’s market cap is ₹26.70B.
When is Hikal Limited’s upcoming earnings report date?
Hikal Limited’s upcoming earnings report date is Aug 12, 2026 which is in 48 days.
How were Hikal Limited’s earnings last quarter?
Hikal Limited released its earnings results on May 27, 2026. The company reported ₹4 earnings per share for the quarter, beating the consensus estimate of N/A by ₹4.
Is Hikal Limited overvalued?
According to Wall Street analysts Hikal Limited’s price is currently Overvalued.
Does Hikal Limited pay dividends?
Hikal Limited pays a Semiannually dividend of ₹0.2 which represents an annual dividend yield of 0.58%. See more information on Hikal Limited dividends here
What is Hikal Limited’s EPS estimate?
Hikal Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hikal Limited have?
Hikal Limited has 123,300,750 shares outstanding.
What happened to Hikal Limited’s price movement after its last earnings report?
Hikal Limited reported an EPS of ₹4 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.217%.
Which hedge fund is a major shareholder of Hikal Limited?
Currently, no hedge funds are holding shares in IN:HIKAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hikal Limited
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, biotechnology, life sciences, animal health, crop protection, and specialty chemicals indusries. It operates through two segments, Pharmaceuticals and Crop Protection. The company also manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. In addition, it offers solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. Further, the company provides anti-convulsant, anti-inflammatory, analgesic, Anti-parasitic, anti-lipemic, anti-histaminic, anti-depressant, anti-psychotic, anti-emetic, anti-diabetic, anti-thrombotic, Anti-viral, anti-hypertensive, and Haemorheologic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, insecticide, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. The company also exports its products. It operates in India, the United States, Canada, Europe, South East Asia, and internationally. The company was formerly known as Hikal Chemical Industries Ltd. and changed its name to Hikal Limited in April 2000. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
Technical Analysis
Indoco Remedies Limited
―
Morepen Laboratories Limited
―
RPG Life Sciences Limited
―
―
Unichem Laboratories Limited
―